SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Onida F,Kantarjian H,Smith T, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002; 99: 840849.
  • 2
    Harris NL,Jaffe ES,Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997. J Clin Oncol. 1999; 17: 38353849.
  • 3
    Beran M,Kantarjian H,O'Brien S, et al. Topotecan, a topoisomerase I inhibitor, is active in treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 1996; 88: 24732479.
  • 4
    Beran M,Estey E,O'Brien S, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol. 1999; 17: 28192830.
  • 5
    Kantarjian H,Beran M,Cortes J, et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer. 2006; 106: 10991109.
  • 6
    Silverman LR,Demakos EP,Peterson BL, et al. Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002; 20: 24292440.
  • 7
    Kantarjian H,Issa JP,Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106: 17941803.
  • 8
    Greenberg P,Cox C,LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 20792088.
  • 9
    Kantarjian H,Oki Y,Garcia-Manero G, et al. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007; 109: 5257.
  • 10
    Cheson BD,Greenberg PL,Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108: 419425.
  • 11
    Quintas-Cardama A,Kantarjian H,O'Brien S, et al. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer. 2006; 107: 15251529.
  • 12
    Beran M,O'Brien S,Thomas D, et al. Phase I study of oral topotecan in hematological malignancies. Clin Cancer Res. 2003; 9: 40844091.